{"id":"W4386705026","doi":"10.1530/erc-22-0301","title":"A phase II study of bevacizumab and temsirolimus in advanced extra-pancreatic neuroendocrine tumors","year":2023,"lang":"en","type":"article","venue":"Endocrine Related Cancer","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; Genentech; Pfizer; Eli Lilly and Company","keywords":"Temsirolimus; Bevacizumab; Medicine; Discontinuation; Adverse effect; Internal medicine; Regimen; Phases of clinical research; Clinical endpoint; Gastroenterology; Progression-free survival; Oncology; Surgery; Toxicity; Chemotherapy; Clinical trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0001252422,0.0004270517,0.001032278,0.001058725,0.0001257964,0.00001425622,0.0002179971,0.0000108469,0.0002394565],"category_scores_gemma":[0.0005144737,0.0003883821,0.0001011215,0.002420224,0.0001687727,0.0002569349,0.0003300629,0.0007976643,0.00002205915],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001433707,"about_ca_system_score_gemma":0.0001726278,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007665619,"about_ca_topic_score_gemma":0.0003317585,"domain_scores_codex":[0.9962128,0.000176493,0.0009797037,0.0008377878,0.000748331,0.001044905],"domain_scores_gemma":[0.998401,0.0002334356,0.0002253888,0.0006576225,0.0001270426,0.0003554758],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.01835061,0.02560287,0.2605371,0.002998952,0.001342562,0.2498063,0.004505351,0.005062137,0.1958363,0.0004112244,0.002585531,0.232961],"study_design_scores_gemma":[0.424519,0.1265634,0.2586633,0.004119734,0.001553155,0.02868547,0.01288814,0.0139626,0.09711789,0.001515831,0.02724086,0.003170599],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9928772,0.002379243,3.782282e-7,0.001234843,0.0001778688,0.002256389,0.00003089466,0.0003192639,0.0007239038],"genre_scores_gemma":[0.9919952,0.002969592,0.00004013467,0.00006010467,0.00005009533,0.0006133156,0.00002393556,0.0001070315,0.004140609],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4061684,"threshold_uncertainty_score":0.9998568,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02371539306775024,"score_gpt":0.3639791544733013,"score_spread":0.3402637614055511,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}